We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 70

Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from


Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs


Summary judgment for impeachment action of Viagra patent upheld by FCA
  • Bereskin & Parr LLP
  • Canada
  • January 24 2014

On January 22, 2014 the Federal Court of Appeal ("FCA") in Pfizer Ireland Pharmaceuticals v Apotex Inc, dismissed an appeal from the judgment of the


“Gene Patent” controversy comes to Canada
  • Bereskin & Parr LLP
  • Canada, USA
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to


Biosimilar Approvals in the US and Canada - the ‘Patent Dance’
  • Bereskin & Parr LLP
  • Canada, USA
  • December 30 2015

The US and Canada each provide an abbreviated pathway (or shortcut) for a biosimilar manufacturer to get a product approved. The shortcut allows for a


Looking into the Crystal Ball - Protecting Polymporphs to Lengthen the Drug Patent Life Cycle
  • Bereskin & Parr LLP
  • Canada, USA
  • June 7 2016

Innovative pharmaceutical companies are increasingly attempting to patent improved forms of their original drug compound. Crystalline forms of a drug


Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada
  • Bereskin & Parr LLP
  • Canada, Global
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the


USPTO issues new subject matter guidance post-Myriad and Prometheus
  • Bereskin & Parr LLP
  • Canada
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately


Gilead leave to appeal to Supreme Court of Canada dismissed re: FCA decision not to list patent on register due to lack of product specificity under PM(NOC) regulations
  • Bereskin & Parr LLP
  • Canada
  • March 21 2013

In Gilead Sciences Canada Inc. v. Canada (Minister of Health), 2012 FCA 254, the Federal Court of Appeal (FCA) dismissed Gilead's appeal of the